Investigation of Efficacy and Safety of Botulinum Toxin A (Botox-Allergan Inc) in Migraine Headaches

Last updated: February 15, 2016
Sponsor: Yale University
Overall Status: Completed

Phase

2/3

Condition

Chronic Pain

Pain

Oral Facial Pain

Treatment

N/A

Clinical Study ID

NCT00660192
0709003056
  • Ages > 18
  • All Genders

Study Summary

The hypothesis of this study is that injection of botulinum toxin A into the muscles around the head (frontal, temporal, posterior neck, occipital) can reduce the intensity and frequency of migraine headaches by 50%.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Adults 18 and older

  • Migraine for more than three months, that fail to respond to two or more majoranti-migraine drug, meeting criteria of chronic migraine

Exclusion

Exclusion Criteria:

  • Age below 18

  • Pregnant or may become pregnant

  • Disease of neuromuscular junction or drugs that affect N-M junction

  • Allergy to Botox

  • Previous use of Botox for migraine by similar methodology

Study Design

Total Participants: 25
Study Start date:
January 01, 2008
Estimated Completion Date:
July 31, 2015

Study Description

Contact PI for study details

Connect with a study center

  • Yale Physician's Building, 800 Howard Ave, lower level,

    New Haven, Connecticut 06510
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.